Clinical trials: Schizophrenia
Comparing Hospitalisation Time With Seroquel and Seroquel Prolong
Nis Register Study Comparing Seroquel and Seroquel Prolong
The general aim of this non interventional study is to clarify what are the current clinical treatment practices of Quetiapine Immediate Release and Quetiapine Extended Release.
- Trial name
- NCT00965536
- Where
- Finland
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Schizophrenia
Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
This study is designed to evaluate the effects of a single dose of SEP-363856 in healthy male and female volunteers with high or low schizotype characteristics.
- Trial name
- NCT01972711
- Testing
- SEP-363856, Amisulpride
- Where
- 2 sites in United Kingdom
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
MEtformin and Lorcaserin for WeighT Loss in Schizophrenia
Purpose: The purpose of this study is to test new pharmacologic strategies for weight loss in patients with schizophrenia, a population for which no current weight-loss treatments have gained widespread use.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Overweight
- Trial name
- MELT (NCT02796144)
- Testing
- Lorcaserin, Metformin
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia, Cardiovascular Disease
Direct Measurements of Cardiometabolic Risk in Treated Schizophrenia Patients
Participants will be asked to do the following: 1. A screening session in which you will take part in a diagnostic interview that will take about 2-3 hours to complete and will address your medical history.
- Trial name
- NCT00501163
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Healthy
Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers
This study aims to assess the safety, tolerability, and pharmacokinetics of PF-04958242 at a number of single ascending doses in healthy volunteers
- Trial name
- NCT02228395
- Testing
- PF-04958242
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Biogen
Schizophrenia, Schizoaffective Disorder
Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is safe and tolerable long term among clinically stable patients.
- Trial name
- NCT00641745
- Testing
- Lurasidone HCl, Risperidone
- Where
- 73 sites in United States, Argentina and 6 more
- Volunteers
- 629 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been…
- Trial name
- NCT04115319
- Testing
- SEP363856, quetiapine XR
- Where
- 42 sites in United States, Romania and 2 more
- Volunteers
- 305 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Autism Spectrum Disorder
A Computational Neuroscience Perspective on the Shared Social Cognitive Deficits of Autism and Schizophrenia
This retrospective cohort study will examine shared neural mechanisms of social cognitive deficits in adults with autism spectrum disorder and adults with schizophrenia using existing clinical, behavioral, and neuroimaging data…
- Trial name
- NCT07618767
- Where
- Taiwan
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Schizophrenia
Bifrontal and Bitemporal Electroconvulsive Therapy (ECT) in Treatment of Patients With Schizophrenia
Electroconvulsive therapy has been used in clinical practice since 1938, a number of randomized trials found significant differences favoring ECT in response rates between individuals with depression receiving real and sham ECT.
- Trial name
- ESBECT (NCT02511509)
- Testing
- Bifrontal electroconvulsive therapy, Bitemporal electroconvulsive therapy
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Medical University of Lodz
Schizophrenia
Antipsychotic Discontinuation in High-risk Subjects
Would be there any difference in dopamine synthesis between remitted clinical high risk subjects for psychosis and healthy control? What would happen to dopamine synthesis after antipsychotic discontinuation in clinical high risk…
- Trial name
- NCT01758887
- Where
- South Korea
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia, Communication
The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong
The Two-Way Communication Checklist (2-COM) is a communication tool developed by van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and…
- Trial name
- NCT02435784
- Testing
- The Two-Way Communication Checklist, Treatment as usual
- Where
- Hong Kong
- Volunteers
- 84 people
- Sponsor
- The University of Hong Kong
Schizophrenia
Fingolimod in Schizophrenia Patients
This will be a single site safety and proof of concept study conducted at the Indiana University Psychotic Disorders Program. Forty subjects with schizophrenia or schizoaffective disorders will be randomized 1:1 to double-blind…
- Trial name
- STEP (NCT01779700)
- Testing
- Fingolimod
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Indiana University
Schizophrenia
The Effectiveness of the Meta-cognitive Training Among Patients With Chronic Schizophrenia
The aim of the study is to compare the effectiveness of the meta-cognitive training (MCT) for schizophrenia against treatment as usual (TAU) among patients who attends community support groups.
- Trial name
- NCT02187692
- Testing
- MCT
- Where
- Poland
- Volunteers
- 50 people
- Sponsor
- Medical University of Warsaw
Schizophrenia
Study of SPG302 in Adults With Schizophrenia
This Phase 2 study described herein will evaluate the safety, efficacy, tolerability, and pharmacodynamics of SPG302 in adults with a primary diagnosis of schizophrenia.
- Trial name
- NCT06442462
- Testing
- SPG302
- Where
- 3 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Spinogenix
Schizophrenia Disorders
Effect of AQW051 on Cognitive Function in Patients With Chronic Stable Schizophrenia
This PoC study is designed to assess the cognitive effects of doses of AQW051 in patients with chronic stable schizophrenia.
- Trial name
- NCT01163227
- Testing
- AQW051 2 mg (single and multiple doses), AQW051 15mg (single and multiple doses), AQW051 100mg (single dose), and 50mg (multiple doses)
- Where
- 2 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia and Related Disorders
Alternative Stimulation Mode and Location for Auditory Hallucination Neuromodulation Treatment
The purpose of the study is to test the hypothesis that functionally navigated repetitive TMS stimulations to the prefrontal cortex (PFC) modulate aberrant cortical electrical activities at PFC circuitry.
- Trial name
- NCT02916810
- Testing
- Active rTMS stimulation
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- The University of Texas Health Science Center, Houston
Bipolar I Disorder, Schizophrenia
Study in Adolescents With Schizophrenia or Bipolar Disorder
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
- Trial name
- NCT00982020
- Testing
- Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
- Where
- 14 sites in United States, Poland and 2 more
- Volunteers
- 203 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizoaffective Disorder
Mobile-Assisted Cognitive Behavior Therapy for Negative Symptoms in Schizophrenia
This clinical trial will test a combined group therapy plus mobile cognitive behavioral therapy intervention targeting defeatist attitudes in consumers with schizophrenia in order to change motivational negative symptoms linked…
- Trial name
- mCBTn (NCT03179696)
- Testing
- Mobile-assisted CBT
- Volunteers
- 31 people
- Sponsor
- Eric Granholm
Schizophrenia, Schizoaffective Disorder
BXCL501 for Agitation in Schizophrenia
Agitation is characterized by excessive motor or verbal activity, irritability, uncooperativeness, threatening gestures, and, in some cases, aggressive or violent behavior.
- Trial name
- DEX (NCT03708315)
- Testing
- Dexmedetomidine Hydrochloride
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Yale University